Nosopharm’s anti-infective pipeline focuses on the treatment of infectious diseases, particularly in the context of antimicrobial resistance.
Our lead R&D programs are based on our unique expertise in the exploitation of the bacteria Photorhabdus and Xenorhabdus.
NOSO-502 IS NOSOPHARM’S FIRST CLINICAL CANDIDATE IN THE NEW CLASS OF ANTIBIOTICS CALLED ODILORHABDINS AND DISCOVERED FROM A XENORHABDUS BACTERIA.
NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp.
NOSO-502 inhibits the bacterial ribosome with a new mechanism of action. It is active against the Carbapenem-Resistant Enterobacteriaceae (CRE), whatever their profile of carbapenemase production. These pathogens are responsible for severe and life-threatening hospital-acquired infections: the WHO classifies them as critical priority pathogens for which new antibiotics are urgently needed.
NOSO-2G is a second-generation Odilorhabdin antibiotic at early preclinical stage. It is active against Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Acinetobacter baumannii.
These pathogens are responsible for life-threatening respiratory hospital-acquired infections: the WHO classifies them as critical priority pathogens for which new antibiotics are urgently needed. NOSO-2G is intended for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), including infections caused by multidrug-resistant pathogens.
Nosopharm develops other R&D programs in the field of infectious diseases stemming from its Photorhabdus & Xenorhabdus based drug discovery platform. Screening campaigns are on-going to discover novel classes of antifungals for the treatment of invasive candidiasis caused by the emerging multidrug-resistant pathogens such as Candida auris and Candida glabrata.
The discovery and development of NOSO-502 and NOSO-2G have been funded in part with financial support from Bpifrance and Région Occitanie / Pyrénées-Méditerranée under grant agreement A1010014J, from Direction Générale de l’Armement (DGA), Ministère des Armées, et Direction Générale des Entreprises, Ministère de l’Economie, des Finances et de la Relance under grant agreement RAPID 122906117, from the Innovative Medicines Initiative Joint Undertaking under grant agreement No 115583, resources of which are comprised of financial contributions from the European Union’s seventh framework program (FP7/2007-2013) and EFPIA companies’ in-kind contribution, from Bpifrance under agreement DOS0063094/00, and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853979: “GNA NOW: Gram-Negative Antibacterials NOW”, the JU receiving support from the European Union’s Horizon 2020 research and innovation programme and the EFPIA company Evotec’s in-kind contribution and being part of the AMR Accelerator.